October 28, 2019 - Advicenne Presented Additional Efficacy Data on ADV7103 in the Treatment of dRTA at International Pediatric Nephrology Association Congress

September 27, 2019 - Advicenne Publishes its 2019 Half-Year Financial Report

September 24, 2019 - Advicenne Presents 2019 Half-Year Financial Report and Confirms Financial Outlook

September 20, 2019 - Advicenne to present eight posters on the positive results of ADV7103 in the treatment of rare nephrological diseases at major international conferences

September 4, 2019 - Advicenne secures production of ADV7103 through long-term manufacturing supply agreement with Elaiapharm Lundbeck

September 3, 2019 - Advicenne to attend the J.P. Morgan Pan European Small / Mid Cap Conference in London

August 29, 2019 - Advicenne Announces First Patient Enrolled in US ARENA-2 Pivotal Phase III Clinical Trial Evaluating ADV7103 in distal Renal Tubular Acidosis (dRTA)

July 26, 2019 - Advicenne to Present at the Solebury Trout European Biotech Investor Day in NYC

July 18, 2019 - Financial Visibility and Accelerated Development

June 13, 2019 - Advicenne confirms prevalence of distal renal tubular acidosis (dRTA) and cystinuria at ISPOR conference

June 12, 2019 - Advicenne announces the successful listing of its shares on the regulated market of Euronext Brussels

May 23, 2019 - Advicenne announces its intention to list on the regulated market of Euronext Brussels

April 30, 2019 - Advicenne Publishes its 2018 Annual Financial Report

April 9, 2019 - Advicenne to attend Smallcap Event 2019 on April 16-17, 2019 in Paris

March 21, 2019 - Advicenne Reports Full Year 2018 Financial Results and Confirms Operational Outlook for 2019

March 12, 2019 - Advicenne Announces Submission of European Marketing Authorization Application (MAA) for ADV7103 as Treatment for Distal Renal Tubular Acidosis (dRTA)

January 7, 2019 - Advicenne’s Flagship ADV7103 Receives Authorization for Pivotal Phase II/III Cystinuria Study in Belgium

December 21, 2018 - Advicenne Publishes its Financial Calendar for 2019

October 26, 2018 - Advicenne Wins Prestigious Prix Galien – Medstartup Award for Best Innovative Trial Design Leading to Quicker and Better Therapeutic Outcomes

October 15, 2018 - Advicenne Receives Health Canada Clearance to Extend its Pivotal Phase III Trial of ADV7103 in Canada

October 4, 2018 - Advicenne to present additional data on ADV7103 at the European Society for Paediatric Nephrology during its 51st Annual Meeting

September 25, 2018 - Advicenne Prepares its Expansion with Highly Experienced Industry Professionals

September 20, 2018 - Advicenne Reports First-Half 2018 Results and Confirms Outlook for 2018

September 12, 2018 - Advicenne receives approval for Marketing Authorization for ADV6209 in Pediatric Moderate Sedation

September 11, 2018 - Advicenne to host a conference call on September 12, 2018 at 6 pm to comment its recent development

September 5, 2018 - Advicenne announces FDA clearance of IND to commence pivotal Phase 3 trial of ADV7103 for distal Renal Tubular Acidosis

July 2, 2018 - Advicenne confirms ADV7103’ safety and efficacy after 24 months in the Phase III Extension Study

May 31, 2018 - Advicenne Announces ADV7103 Poster Presentation at the 55th European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress

May 15, 2018 - Advicenne enters into partnership with the European Society for Paediatric Nephrology (ESPN) aiming to improve patient care for distal Renal Tubular Acidosis (dRTA) in Europe

May 4, 2018 - Advicenne receives authorisation from French regulation authorities to initiate pivotal phase II/III trial of ADV7103 in Cystinuria

April 30, 2018 - Advicenne publishes its annual financial report

April 10, 2018 - Advicenne 2017 Financial Results and Operational Perspectives for 2018

February 12, 2018 - Advicenne announces its financial calendar for 2018 and cash position as of December 31st, 2017

January 24, 2018 - Advicenne appoints Linda Law, MD as US Vice President, Clinical Development and Medical Affairs

January 5, 2018 - Partial exercise of over – allotment option

November 6, 2017 - ADV7103 : Résultats étude suivi 6 mois

November 6, 2017 - ADV7103: 6-month data presented at ASN

October 31, 2017 - Document de base

September 20, 2017 - Advicenne présente un poster à l’occasion de la 9e conférence EuPFI sur l’ADV7103, un produit innovant adapté en fonction de l’âge visant à traiter l’acidose tubulaire rénale distale

September 20, 2017 - Advicenne to Present a Poster at the 9th EuPFI Conference on ADV7103, an Innovative age-adapted Product for distal Renal Tubular Acidosis

September 11, 2017 - Advicenne annonce le succès des résultats positifs des données cliniques de l’étude pivot de Phase III pour l’ADV7103 pour les adultes et les enfants souffrant d’acidose tubulaire rénale distale

September 11, 2017 - Advicenne Announces Positive Pivotal Phase III Clinical Data for ADV7103 in Adults and Children Suffering from distal Renal Tubular Acidosis

July 2, 2017 - Advicenne se voit accorder la Désignation de médicament orphelin par l’UE pour l’ADV7103 pour le traitement de la tubulopathie rénale distale

July 2, 2017 - Advicenne Receives Orphan Drug Designation from the EU for ADV7103 for the Treatment of distal Renal Tubulopathy

June 21, 2017 - Advicenne présente les résultats préliminaires des données cliniques de l’étude en Phase III de l’ADV7103 à l’occasion de la prochaine réunion annuelle de la Société européenne de néphrologie pédiatrique

June 21, 2017 - Advicenne to Present Preliminary Phase III Clinical Data on ADV7103 at the Upcoming European Society of Paediatric Nephrology’s Annual Meeting

March 20, 2017 - Advicenne annonce la clôture de la levée de fonds de 16 millions d’euros

March 20, 2017 - Advicenne Announces the Closing of a €16 Million Financing Round

September 1, 2016 - Advicenne nomme Ludovic Robin en tant que Responsable commercial et Chargé de stratégie

September 1, 2016 - Advicenne appoints Ludovic Robin as Chief Business & Strategy Officer

February 23, 2016 - Advicenne Pharma vend son médicament potentiel ADV 6209 pour la sédation modérée à la société suisse Primex Pharmaceuticals

February 23, 2016 - Advicenne Pharma sells its drug candidate ADV6209 for moderate sedation to the Swiss Primex Pharmaceuticals

April 23, 2015 - Accord pour l’autorisation de la commercialisation en France du Levidcen

April 23, 2015 - French marketing authorization approval for Levidcen

February 20, 2014 - Advicenne a signé un accord de licence avec Desitin portant sur un nouvel antiépileptique pour le marché français, les micro-granules Levidcen

February 20, 2014 - Advicenne has signed a license agreement with Desitin, on a new anti-epileptic for the French market, Levidcen micro-granules

February 1, 2014 - Advicenne accueille Catherine Martre au sein de son équipe en qualité de Responsable de la stratégie et du développement commercial

Advicenne's, company dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology.

Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Paris and Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France.

Contact Us

14 + 5 =

© 2019 Advicenne